Standard Care | Minimal Risk

Berberine (MURINE RELIEF berberine chloride 0.26mg/mL eye drops bottle)

What to know about Berberine — also sold as MURINE RELIEF berberine chloride 0.26mg/mL eye drops bottle: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Berberine (brand names: MURINE RELIEF berberine chloride 0.26mg/mL eye drops bottle) is classified as Minimal risk by AllMeds. Natural supplement with glucose-lowering effects, minimal workplace safety impact.

Key Takeaways

  • Risk level: Minimal (0 points)

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) Unscheduled Not PBS listed

Risk Profile

Risk Level Minimal
Risk Points 0
CNS Depressant No
Respiratory Risk No

Natural supplement with glucose-lowering effects, minimal workplace safety impact.

How Berberine is regulated

Berberine is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Australia TGA / PBS / State Schemes

Classified as Unscheduled under the Therapeutic Goods Administration (TGA).

Check this medication against your full medication list

Run a full risk assessment including Berberine interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.